# Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

> **NCT03373903** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Restorbio Inc.** · enrollment: 652 (actual)

## Conditions studied

- Respiratory Tract Infections

## Interventions

- **OTHER:** Placebo
- **DRUG:** BEZ235
- **DRUG:** BEZ235 plus everolimus (RAD001)

## Key facts

- **NCT ID:** NCT03373903
- **Lead sponsor:** Restorbio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-15
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-07
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2018-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373903, "Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03373903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*